Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

NCT01120275 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Acral Lentiginous Malignant Melanoma
Lentigo Maligna Malignant Melanoma
Nodular Malignant Melanoma
Recurrent Melanoma
Solar Radiation-related Skin Melanoma
Stage IV Melanoma
Superficial Spreading Malignant Melanoma

Interventions

DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)